Overview

Intravenous Remifentanil for Labor Analgesia

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Labor analgesia is an essential health caring procedure for women. However, epidural analgesia cannot be performed on all subjects for different contraindications, such as lower platelet counter, back infection at the puncture site, and fear of epidural injection etc. Therefore, intravenous analgesia is an alternative for such conditions. Given the influence of intravenous administration of drugs on fetus, the drug selection is very important. Remifentanil, a super-short efficacious opioid, can last for 3-4 minutes after injection, which is similar in both maternal and fetal environment. Thus the fetus-associated side effects would be less than other drugs. The investigators hypothesized that remifentanil would be a superior intravenous drug used with patient-controlled technique for labor analgesia.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing Medical University
Collaborator:
HRSA/Maternal and Child Health Bureau
Treatments:
Hydromorphone
Remifentanil